Summary When the British HIV-1 Association (BHIVA) guidelines on the treatment of HIV-
seropositive individuals with antiretrovirals were published in The Lancet in April 1997, it …

Background: Current antiretroviral treatment can induce significant and sustained virological
and immunological responses in HIV-1-infected persons over at least the short-to mid-term …

ContextThe long-term adverse effects, expense, and difficulty of adherence to antiretroviral
regimens have led to studies of simpler maintenance therapies. Maintenance therapy with …

The M184V mutation in the HIV‐1 reverse transcriptase gene is primarily associated with
rapid, high‐level lamivudine (3TC) resistance. It has also been observed to arise under …

Stavudine is a thymidine nucleoside analogue which is phosphorylated intracel-lularly to an
active metabolite, stavudine 5′-triphosphate. This metabolite inhibits HIV replication, either …

Objective: To investigate the feasibility of ritonavir-boosted atazanavir monotherapy in HIV-1-
infected patients with stable antiretroviral therapy (ART). Design: Single-armed single-center …

Objective To compare changes in quality of life (QoL) over 96 weeks in patients enrolled in a
triple-therapy protocol, a treatment-intensification protocol, or an induction-maintenance …

HIV-1-infected patients with suppressed plasma viral loads often require changes to their
antiretroviral (ARV) therapy to manage drug toxicity and intolerance, to improve adherence …

Design Multicenter, partially blinded, prospective, randomized study of 202 HIV-infected
subjects to determine whether therapy intensification improves long-term rates of virologic …

A unique and unexpected syndrome consisting of metabolic abnormalities (hyperlipidaemia
and insulin resistance) and body fat redistribution (central adiposity and peripheral fat …